<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01163071</url>
  </required_header>
  <id_info>
    <org_study_id>CA601</org_study_id>
    <nct_id>NCT01163071</nct_id>
  </id_info>
  <brief_title>A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas</brief_title>
  <official_title>A Phase I Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the MTD and/or RP2D of ABI-011 when administered by&#xD;
      IV on Day 1, Day 8 and Day 15 with one week of rest for patients with advanced solid tumor&#xD;
      malignancies and lymphomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose limiting toxicities (DLT), maximum tolerated dose (MTD)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">March 1, 2011</start_date>
  <completion_date type="Actual">September 23, 2011</completion_date>
  <primary_completion_date type="Actual">September 23, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT's and MTD Safety and Toxicity profile</measure>
    <time_frame>During Cycle 1, treatment period, End of Study and Follow-Up, approximately up to 2 years</time_frame>
    <description>Evaluate PK and PD of ABI-011. Preliminary assessment of tumor response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and toxicity profile of repeated dosing of ABI-011</measure>
    <time_frame>End of study and follow up, approximately up to 2 years</time_frame>
    <description>Number of subjects with Adverse Events; laboratory assessments, ECG assessments, opthalmologic assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate plasma PK of ABI-011 on this schedule</measure>
    <time_frame>End of Study and follow-up, Up to two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess biological activity and PD of ABI-011</measure>
    <time_frame>End of study and follow-up, approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Make preliminary assessment of tumor response</measure>
    <time_frame>End of study and follow-up, approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess biological activity/exploratory during treatment C1, C2, EOS</measure>
    <time_frame>End of Study and follow-up, aproximately two years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ABI-011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-011</intervention_name>
    <description>ABI-011</description>
    <arm_group_label>ABI-011</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be equal or greater 18 years of age&#xD;
&#xD;
          -  ECOG performance status less than or equal to 2 (Appendix 2)&#xD;
&#xD;
          -  Pts. must be willing and able to sign informed consent&#xD;
&#xD;
          -  Cytologically or histologically confirmed solid tumor malignancy or lymphoma for which&#xD;
             no standard approved therapy is available. Patients should have accessible tumor&#xD;
             lesions amendable to 2 serial biopsies which would not put the patient or their&#xD;
             treatment at risk&#xD;
&#xD;
          -  Pt. agrees and is willing to provide 2 serial tumor biopsies(optional on first phase,&#xD;
             mandatory on 2nd phase)&#xD;
&#xD;
          -  During the dose escalation phase, measurable or non-measurable disease as defined by&#xD;
             RECIST criteria. At 2nd phase, only patients with measurable disease&#xD;
&#xD;
          -  Life expectancy of equal or greater than 12 weeks&#xD;
&#xD;
          -  All AEs of any prior chemotherapy, surgery or radiotherapy, must have resolved to&#xD;
             grade equal to or less than 1&#xD;
&#xD;
          -  The following laboratory results must be present within 14 days of initial ABI-011&#xD;
             administration&#xD;
&#xD;
               -  Hemoglobin greater or equal to 9g/dL&#xD;
&#xD;
               -  Absolute neutrophils count(ANC)greater or equal to 1.5 x 10^9/L&#xD;
&#xD;
               -  Platelet count is greater or equal to 100 x 10^9/L&#xD;
&#xD;
               -  Serum bilirubin less than or equal to 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Aspartate transaminase (AST) and alanine transaminase (ALT)is less than or equal&#xD;
                  to 2.5 ULN(except if liver metastases are present; then values must be less than&#xD;
                  or equal to 5 x ULN)&#xD;
&#xD;
               -  Potassium, corrected calcium and magnesium WNL&#xD;
&#xD;
               -  Serum Creatinine less than or equal to 1.5 x ULN&#xD;
&#xD;
               -  Activated aPTT,PT,INR,WNL&#xD;
&#xD;
               -  WNL levels : Troponin I and T, CK-MB,BNP&#xD;
&#xD;
          -  At least one measurable lesion should be evaluable (DCE-MRI eligibility criteria)and&#xD;
             meet at least one of the criteria below:&#xD;
&#xD;
               -  At least one measurable lesions should be at least 3 cm in diameter and should&#xD;
                  not be near the diaphragm or mediastinum&#xD;
&#xD;
               -  Lesions should be solid masses that enhance with contrast, without signs of&#xD;
                  calcification on the most recent computed tomography (CT) or magnetic resonance&#xD;
                  (MRI)scan&#xD;
&#xD;
          -  Pts. must be willing to practice contraceptive methods for the duration of the study&#xD;
             and for one month following study completion. Female patients must be postmenopausal,&#xD;
             surgically sterile or they must agree to use acceptable methods of birth control. Male&#xD;
             patients must be surgically sterile or agree to use an acceptable method of&#xD;
             contraception.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test(B-hCG)within&#xD;
             72 hours prior to first study drug administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to comply with study and follow-up procedures&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Treatment with chemotherapy, hormonal therapy(except leuprolide for prostate cancer),&#xD;
             immunotherapy, biologic therapy, or radiation therapy as cancer therapy within 4 weeks&#xD;
             before initiation of study treatment. Six weeks should have elapsed if prior&#xD;
             chemotherapy treatment included nitrosoureas or mitomycin C&#xD;
&#xD;
          -  Pts. who have received antibody-based therapies within 28 days or 5 half-lives of the&#xD;
             agent, whichever time period is longer&#xD;
&#xD;
          -  Major surgery within 6 weeks before first study drug administration&#xD;
&#xD;
          -  Prior treatment with tumor vascular disruptive agents&#xD;
&#xD;
          -  Any uncontrolled medical or psychiatric risk factors&#xD;
&#xD;
          -  Central nervous system(CNS)metastases.&#xD;
&#xD;
          -  History of diabetic retinopathy. All patients must be evaluated by an ophthalmologist&#xD;
             prior to study treatment&#xD;
&#xD;
          -  Any history of myopathy, either peripheral or cardiac&#xD;
&#xD;
          -  Current use of medications that may have the potential of QTc prolongation&#xD;
&#xD;
          -  History of allergy or hypersensitivity to any compound of the ABI-011 formulation&#xD;
&#xD;
          -  Active uncontrolled bacterial, viral, or fungal infection, requiring systemic therapy&#xD;
&#xD;
          -  Pt.has known infection with human immunodeficiency virus (HIV),or known chronic&#xD;
             Hepatitis B or Hepatitis C&#xD;
&#xD;
          -  Inability to be venipunctured and/or tolerate venous access&#xD;
&#xD;
          -  History of other carcinoma within past 5 years&#xD;
&#xD;
          -  Pts. requiring therapeutic anticoagulation with either coumadin or low molecular&#xD;
             weight heparin or with history of any bleeding diathesis. Low dose aspirin and low&#xD;
             dose coumadin for catheter maintenance are allowed&#xD;
&#xD;
          -  Lung tumors in a central position.&#xD;
&#xD;
          -  Cardiac exclusion criteria:&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF)&lt; 50% by echocardiography;&#xD;
&#xD;
               -  Previous history of MI or ischemic heart disease&#xD;
&#xD;
               -  EKG findings suggestive of current or previous ischemic heart disease, including&#xD;
                  left bundle branch block&#xD;
&#xD;
               -  Prior treatment with chemotherapy agents known to potentially cause&#xD;
                  cardiotoxicity&#xD;
&#xD;
               -  Class III or IV heart failure as defined by the New York Heart(NYHA) functional&#xD;
                  classification&#xD;
&#xD;
               -  Congenital or acquired long QT syndrome&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Current or past history of clinically significant arrhythmias&#xD;
&#xD;
               -  QTc prolongation&#xD;
&#xD;
               -  HO Symptomatic PVD (Venous or arterial)&#xD;
&#xD;
          -  Seizure disease requiring current anticonvulsant treatment&#xD;
&#xD;
          -  HO previous CVA or TIA&#xD;
&#xD;
          -  HO inflammatory bowel disease (active or past) or active PUD&#xD;
&#xD;
          -  HO previous, whole abdomen radiation therapy or more than Grade 1 residual toxicity&#xD;
             from previous radiation therapy.&#xD;
&#xD;
          -  History of autoimmune disease or vascular disease (venous or arterial)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia M LoRusso, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karmanos Cancer Institute Hudson-Webber Cancer Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Sarantopoulos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Therapy Research Center at the University Health Sciences Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karmanos Cancer Center Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTRC @ The Utah Health Science Center @ San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 15, 2010</study_first_submitted>
  <study_first_submitted_qc>July 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2010</study_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

